Team develops treatment effective against lethal Marburg virus

August 20, 2014, University of Texas Medical Branch at Galveston
An electron microscope photo of the Marburg virus. Credit: Thomas Geisbert, University of Texas Medical Branch

For the first time, researchers at the University of Texas Medical Branch at Galveston, in collaboration with Tekmira Pharmaceuticals, have protected nonhuman primates against Marburg virus – Angola hemorrhagic fever. Their treatment was shown to be effective at a point when animals have detectable levels of the virus in their system and begin to show symptoms of the disease. The study appears in the August 20 edition of the journal Science Translational Medicine.

There are currently no vaccines or drugs approved for human use and no post-exposure treatment that has completely protected nonhuman primates against MARV-Angola, the most deadly Marburg viral strain, with a mortality rate of up to 90 percent. This virus, which is in the same family as Ebola, has a rapid disease course (seven to nine days) in nonhuman primates. There have been two recent imported cases of MARV HF to Europe and the United States, further increasing concern regarding the public health threat posed by this deadly virus.

"The increasingly frequent outbreaks of filoviral HF in Africa evidenced by the current rapidly spreading outbreak in Guinea, Liberia and Sierra Leone illustrate the clear and present danger filoviruses represent to human health," stated UTMB's Thomas Geisbert, professor of microbiology and immunology. "As such, the development of effective countermeasures against these viruses is a critical need."

Previous studies with nonhuman primates have examined countermeasures against MARV infection at times before the subjects showed any evidence of clinical illness. This goal of this study, led by Geisbert and Ian MacLachlan, executive vice president and chief technical officer of Tekmira Pharmaceuticals, was to determine whether it is possible to protect animals against a lethal MARV-Angola infection when treatment was started at a point when animals have detectable levels of the virus in their system and show the first clinical signs of disease.

Their strategy centered on the MARV RNA genome that encodes for seven structural proteins, two of which are responsible for replicating the genome. These seven genes and their products represent targets for the development of therapeutic agents and vaccines against MARV.

The research team demonstrated that their lipid encapsulated small interfering RNA treatment completely protected against lethal MARV-Angola HF when treatment began even up to three days following infection.

"The significance of delaying until three days after infection, which is the earliest time at which diagnosis by viral RNA can be detected and those infected show the first clinical signs of disease, is a critical step in triggering clinical interventions," stated MacLachlan.

Explore further: Researchers one step closer to countering deadly Nipah virus

More information: "Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA," by E. Thi et al. Science Translational Medicine, stm.sciencemag.org/lookup/doi/ … scitranslmed.3009706

Related Stories

Researchers one step closer to countering deadly Nipah virus

June 25, 2014
An interdisciplinary research team from the University of Texas Medical Branch at Galveston, the Uniformed Services University of the Health Sciences and three groups within the National Institutes of Health reports a new ...

Novel drug treatment protects primates from deadly Marburg virus

March 4, 2014
For the first time, scientists have demonstrated the effectiveness of a small-molecule drug in protecting nonhuman primates from the lethal Marburg virus. Their work, published online in the journal Nature, is the result ...

Scientists identify protective role for antibodies in Ebola vaccine study

January 14, 2013
Researchers at the National Institutes of Health (NIH) and Oregon Health & Science University (OHSU) have found that an experimental vaccine elicits antibodies that can protect nonhuman primates from Ebola virus infection.

Post-exposure antibody treatment protects primates from Ebola, Marburg viruses

March 13, 2012
Army scientists have demonstrated, for the first time, that antibody-based therapies can successfully protect monkeys from the deadly Ebola and Marburg viruses. In addition, the animals were fully protected even when treatment ...

Transmission of hepatitis C virus following antiviral treatment

July 8, 2014
Millions of people throughout the world are infected with hepatitis C virus (HCV). Left untreated, infection results in serious complications such as cirrhosis of the liver and cancer. Many HCV-infected patients respond well ...

Recommended for you

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

Researchers define possible molecular pathway for neurodegeneration in prion diseases

September 21, 2018
A new study has shed light on the mechanisms underlying the progression of prion diseases and identified a potential target for treatment.

Fighting a deadly parasite: Scientists devise a method to store Cryptosporidium, aiding vaccine research efforts

September 21, 2018
In May, just before one of the hottest summers on record, the U.S. Centers for Disease Control and Prevention issued a warning about diseases lurking in recreational water facilities like swimming pools and water playgrounds. ...

Scientists make significant discovery in the fight against drug-resistant tuberculosis

September 20, 2018
A team of scientists have identified a naturally occurring antibiotic that may help in the fight against drug-resistant Tuberculosis.

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.